WHO Launches New Phase of Solidarity Trial to Test 3 New Anti-COVID-19 Drugs
Geneva - The World Health Organization (WHO) said on Wednesday that it was starting the next phase of its Solidarity trial to test three new drugs in hospitalized COVID-19 patients. "The World Health Organization (WHO) has announced the next phase in its Solidarity trial: Solidarity PLUS will enroll hospitalized patients to test three new drugs in hospitalized COVID-19 patients.
These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients," the WHO said. The drugs in question were donated for the trial by their manufacturers, the statement noted, adding that they are already used against other diseases — artesunate for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients," the WHO said. The drugs in question were donated for the trial by their manufacturers, the statement noted, adding that they are already used against other diseases — artesunate for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.